Skip to main content

Table 3 Associations between changes in (hydroxy)methylation and in DAS28 over the first 3 months of therapy

From: Higher baseline global leukocyte DNA methylation is associated with MTX non-response in early RA patients

 

ΔMethylation

ΔHydroxymethylation

 

Biomarkers

B (SE)

β

p

B (SE)

β

p

1

Δ(hydroxy)methylation

− 0.50 (0.60)

− 0.07

0.403

− 9.32 (19.40)

− 0.04

0.632

2

Δ(hydroxy)methylation

− 0.68 (0.51)

− 0.09

0.182

− 1.55 (16.35)

− 0.01

0.925

 

DAS28

− 0.51 (0.07)

− 0.51

< 0.001

− 0.52 (0.07)

− 0.51

< 0.001

 

Erythrocyte folate (nmol/L)

− 1.00 × 10−3 (2.00 × 10−4)

− 0.15

0.027

− 1.00 × 10−3 (2.00 × 10−4)

− 0.16

0.024

 

BMI (kg/m2)

0.05 (0.03)

0.19

0.005

0.04 (0.02)

0.18

0.008

 

Age (years)

0.01 (0.01)

0.10

0.134

0.01 (0.01)

0.11

0.130

 

Sex

 

–

 

0.20 (0.17)

0.08

0.240

 

Smoking (current)

0.29 (0.17)

0.11

0.086

0.28 (0.17)

0.11

0.101

 

ACPA status (positive)

 

–

  

–

 
 

Observations

 

163

  

161

 
  1. Associations were tested using crude univariate models (1) and adjusted for confounders (2). Potential confounders were baseline DAS28 score, baseline erythrocyte folate levels (nmol/L), BMI (kg/m2), age (years), sex, smoking status (current smoker versus former + never smoker), and ACPA status. Only biomarkers that changed the effect size with > 10% were considered confounders. B beta coefficient, SE standard error, β standardized beta coefficient. p < 0.05 was considered significant
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us